Van Der Vring J A, Daniëls M C, Holwerda N J, Withagen P J, Schelling A, Cleophas T J, Hendriks M G
Merwede Hospital, Dodrecht, Sleidrecht, The Netherlands.
Br J Clin Pharmacol. 1999 May;47(5):493-8. doi: 10.1046/j.1365-2125.1999.00924.x.
The combination of calcium channel blockers and beta-adrenoceptor blockers is more effective for the treatment of exercise-induced angina pectoris than beta-adrenoceptor blocker monotherapy. As ischaemia in exercise-induced angina is preceded by increase in heart rate, calcium channel blockers with negative chronotropic properties may perform better for this purpose than nonchronotropic compounds.
A 335 patient double-blind parallel-group study comparing 14 day treatment with amlodipine 5 and 10 mg, with diltiazem 200 and 300 mg, and mibefradil 50 and 100 mg added to baseline beta-adrenoceptor blocker treatment was performed. Exercise testing (ETT) was performed by bicycle ergometry.
Although none of the calcium channel blockers improved duration of exercise or amount of workload, all significantly delayed onset of 1 mm ST-segment depression on ETT (P<0.001 for any treatment vs baseline). In addition, mibefradil, both low and high dose treatment, produced the longest delays (low dose: different from diltiazem and amlodipine by 24.1 and 29.8 s, respectively, P<0. 003 and <0.001; high dose: different from diltiazem and amlodipine by 33.7 and 37.0 s, respectively, P<0.001 and <0.001). These effects were linearly correlated with the reduction in rate pressure product (RPP). Serious symptoms of dizziness occurred significantly more frequently on mibefradil (P<0.05), and 19 patients on mibefradil withdrew from trial.
Calcium channel blockers with negative chronotropic properties provide greater delay of ischaemia in patients with exercise-induced angina, but the concomitant risk of intolerable dizziness attenuates this benefit.
钙通道阻滞剂与β肾上腺素能受体阻滞剂联合使用治疗运动诱发性心绞痛比单独使用β肾上腺素能受体阻滞剂更有效。由于运动诱发性心绞痛的缺血发生在心率增加之前,具有负性变时作用的钙通道阻滞剂可能比无变时作用的化合物更适合此用途。
进行了一项335例患者的双盲平行组研究,比较在基线β肾上腺素能受体阻滞剂治疗基础上加用5毫克和10毫克氨氯地平、200毫克和300毫克地尔硫䓬以及50毫克和100毫克米贝拉地尔治疗14天的效果。通过自行车测力计进行运动试验(ETT)。
尽管没有一种钙通道阻滞剂能改善运动持续时间或工作量,但所有药物都显著延迟了ETT上1毫米ST段压低的发作(任何治疗与基线相比,P<0.001)。此外,低剂量和高剂量米贝拉地尔治疗产生的延迟最长(低剂量:分别比地尔硫䓬和氨氯地平长24.1秒和29.8秒,P<0.003和<0.001;高剂量:分别比地尔硫䓬和氨氯地平长33.7秒和37.0秒,P<0.001和<0.001)。这些作用与心率血压乘积(RPP)的降低呈线性相关。米贝拉地尔出现严重头晕症状的频率明显更高(P<0.05),有19例服用米贝拉地尔的患者退出试验。
具有负性变时作用的钙通道阻滞剂能更大程度地延迟运动诱发性心绞痛患者的缺血发作,但随之而来的难以耐受的头晕风险削弱了这种益处。